G, B., D, L., I, T., C, G., L, F., E, M., . . . M, T. (2025). New Combination Regimens vs. Fludarabine, Cytarabine, and Idarubicin in the Treatment of Intermediate- or Low-Risk Nucleophosmin-1-Mutated Acute Myeloid Leukemia: A Retrospective Analysis from 7 Italian Centers. Journal of clinical medicine, 14(3), . https://doi.org/10.3390/jcm14030700
Chicago Style (17th ed.) CitationG, Battaglia, et al. "New Combination Regimens Vs. Fludarabine, Cytarabine, and Idarubicin in the Treatment of Intermediate- or Low-Risk Nucleophosmin-1-Mutated Acute Myeloid Leukemia: A Retrospective Analysis from 7 Italian Centers." Journal of Clinical Medicine 14, no. 3 (2025). https://doi.org/10.3390/jcm14030700.
MLA (9th ed.) CitationG, Battaglia, et al. "New Combination Regimens Vs. Fludarabine, Cytarabine, and Idarubicin in the Treatment of Intermediate- or Low-Risk Nucleophosmin-1-Mutated Acute Myeloid Leukemia: A Retrospective Analysis from 7 Italian Centers." Journal of Clinical Medicine, vol. 14, no. 3, 2025, https://doi.org/10.3390/jcm14030700.
